|
US3071618A
(en)
|
1956-02-02 |
1963-01-01 |
Pfizer & Co C |
Diquaternary ammonium salts of n, n, n', n'-tetra substituted alkylene diamines
|
|
GB1351761A
(en)
|
1971-02-04 |
1974-05-01 |
Wilkinson Sword Ltd |
Substituted p-menthane carboxamides and compositions containing them
|
|
US4136163A
(en)
|
1971-02-04 |
1979-01-23 |
Wilkinson Sword Limited |
P-menthane carboxamides having a physiological cooling effect
|
|
JPS5115098A
(ja)
|
1974-07-26 |
1976-02-06 |
Asahi Chemical Ind |
Akurirukeiseniseihinno shorihoho
|
|
US4826689A
(en)
|
1984-05-21 |
1989-05-02 |
University Of Rochester |
Method for making uniformly sized particles from water-insoluble organic compounds
|
|
US4594343A
(en)
|
1984-10-19 |
1986-06-10 |
Shanklin Jr James R |
1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
|
|
GB8810067D0
(en)
|
1988-04-28 |
1988-06-02 |
Ucb Sa |
Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides
|
|
FR2634376B1
(fr)
|
1988-07-21 |
1992-04-17 |
Farmalyoc |
Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
|
|
US4908372A
(en)
|
1988-10-13 |
1990-03-13 |
Merrell Dow Pharmaceuticals Inc. |
Antihistaminic piperidinyl benzimidazoles
|
|
IT1227626B
(it)
|
1988-11-28 |
1991-04-23 |
Vectorpharma Int |
Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
|
|
US5552558A
(en)
|
1989-05-23 |
1996-09-03 |
Abbott Laboratories |
Retroviral protease inhibiting compounds
|
|
BR9106438A
(pt)
|
1990-05-11 |
1993-05-18 |
Pfizer |
Composicoes terapeuticas sinergisticas e processos
|
|
US5821232A
(en)
|
1990-05-11 |
1998-10-13 |
Pfizer Inc. |
Synergistic therapeutic compositions and methods
|
|
DE4018070A1
(de)
|
1990-06-06 |
1991-12-12 |
Bayer Ag |
Morpholinoharnstoff-derivate
|
|
IT1243390B
(it)
|
1990-11-22 |
1994-06-10 |
Vectorpharma Int |
Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
|
|
CA2097317C
(en)
|
1990-12-14 |
2002-02-12 |
Albert A. Carr |
Antiallergic piperdinyl benzimidazoles
|
|
US5145684A
(en)
|
1991-01-25 |
1992-09-08 |
Sterling Drug Inc. |
Surface modified drug nanoparticles
|
|
US5552160A
(en)
|
1991-01-25 |
1996-09-03 |
Nanosystems L.L.C. |
Surface modified NSAID nanoparticles
|
|
WO1993016081A1
(en)
|
1992-02-13 |
1993-08-19 |
Merrell Dow Pharmaceuticals Inc. |
Piperidinyl thiacyclic derivatives
|
|
WO1993025190A1
(en)
|
1992-06-10 |
1993-12-23 |
Eastman Kodak Company |
Surface modified nsaid nanoparticles
|
|
NZ248813A
(en)
|
1992-11-25 |
1995-06-27 |
Eastman Kodak Co |
Polymeric grinding media used in grinding pharmaceutical substances
|
|
US5298262A
(en)
|
1992-12-04 |
1994-03-29 |
Sterling Winthrop Inc. |
Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
|
|
US5346702A
(en)
|
1992-12-04 |
1994-09-13 |
Sterling Winthrop Inc. |
Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
|
|
US5302401A
(en)
|
1992-12-09 |
1994-04-12 |
Sterling Winthrop Inc. |
Method to reduce particle size growth during lyophilization
|
|
US5340564A
(en)
|
1992-12-10 |
1994-08-23 |
Sterling Winthrop Inc. |
Formulations comprising olin 10-G to prevent particle aggregation and increase stability
|
|
US5336507A
(en)
|
1992-12-11 |
1994-08-09 |
Sterling Winthrop Inc. |
Use of charged phospholipids to reduce nanoparticle aggregation
|
|
US5429824A
(en)
|
1992-12-15 |
1995-07-04 |
Eastman Kodak Company |
Use of tyloxapole as a nanoparticle stabilizer and dispersant
|
|
US5352459A
(en)
|
1992-12-16 |
1994-10-04 |
Sterling Winthrop Inc. |
Use of purified surface modifiers to prevent particle aggregation during sterilization
|
|
US5587143A
(en)
|
1994-06-28 |
1996-12-24 |
Nanosystems L.L.C. |
Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
|
|
CA2192836A1
(en)
|
1994-07-29 |
1996-02-15 |
Anthony R. Haight |
Process for the preparation of a substituted 2.5-diamino-3-hydroxyhexane
|
|
US5767144A
(en)
|
1994-08-19 |
1998-06-16 |
Abbott Laboratories |
Endothelin antagonists
|
|
US6162927A
(en)
|
1994-08-19 |
2000-12-19 |
Abbott Laboratories |
Endothelin antagonists
|
|
US6946481B1
(en)
|
1994-08-19 |
2005-09-20 |
Abbott Laboratories |
Endothelin antagonists
|
|
US5585108A
(en)
|
1994-12-30 |
1996-12-17 |
Nanosystems L.L.C. |
Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
|
|
US5560932A
(en)
|
1995-01-10 |
1996-10-01 |
Nano Systems L.L.C. |
Microprecipitation of nanoparticulate pharmaceutical agents
|
|
US5662883A
(en)
|
1995-01-10 |
1997-09-02 |
Nanosystems L.L.C. |
Microprecipitation of micro-nanoparticulate pharmaceutical agents
|
|
US5665331A
(en)
|
1995-01-10 |
1997-09-09 |
Nanosystems L.L.C. |
Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
|
|
US5569448A
(en)
|
1995-01-24 |
1996-10-29 |
Nano Systems L.L.C. |
Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
|
|
US5571536A
(en)
|
1995-02-06 |
1996-11-05 |
Nano Systems L.L.C. |
Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
|
|
US5560931A
(en)
|
1995-02-14 |
1996-10-01 |
Nawosystems L.L.C. |
Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
|
|
US5503723A
(en)
|
1995-02-08 |
1996-04-02 |
Eastman Kodak Company |
Isolation of ultra small particles
|
|
US5534270A
(en)
|
1995-02-09 |
1996-07-09 |
Nanosystems Llc |
Method of preparing stable drug nanoparticles
|
|
US5518738A
(en)
|
1995-02-09 |
1996-05-21 |
Nanosystem L.L.C. |
Nanoparticulate nsaid compositions
|
|
US5622938A
(en)
|
1995-02-09 |
1997-04-22 |
Nano Systems L.L.C. |
Sugar base surfactant for nanocrystals
|
|
US5591456A
(en)
|
1995-02-10 |
1997-01-07 |
Nanosystems L.L.C. |
Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
|
|
US5573783A
(en)
|
1995-02-13 |
1996-11-12 |
Nano Systems L.L.C. |
Redispersible nanoparticulate film matrices with protective overcoats
|
|
US5510118A
(en)
|
1995-02-14 |
1996-04-23 |
Nanosystems Llc |
Process for preparing therapeutic compositions containing nanoparticles
|
|
US5580579A
(en)
|
1995-02-15 |
1996-12-03 |
Nano Systems L.L.C. |
Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
|
|
US5747001A
(en)
|
1995-02-24 |
1998-05-05 |
Nanosystems, L.L.C. |
Aerosols containing beclomethazone nanoparticle dispersions
|
|
US5565188A
(en)
|
1995-02-24 |
1996-10-15 |
Nanosystems L.L.C. |
Polyalkylene block copolymers as surface modifiers for nanoparticles
|
|
US5718919A
(en)
|
1995-02-24 |
1998-02-17 |
Nanosystems L.L.C. |
Nanoparticles containing the R(-)enantiomer of ibuprofen
|
|
WO1998035666A1
(en)
|
1997-02-13 |
1998-08-20 |
Nanosystems Llc |
Formulations of nanoparticle naproxen tablets
|
|
AU7697298A
(en)
|
1997-05-29 |
1998-12-30 |
Eli Lilly And Company |
Process for preparing heterocyclic compounds
|
|
WO1999054321A1
(en)
|
1998-04-21 |
1999-10-28 |
Aventis Pharma Limited |
Substituted diamines and their use as cell adhesion inhibitors
|
|
US6437146B1
(en)
|
1998-09-25 |
2002-08-20 |
Fujisawa Pharmaceutical Co., Ltd. |
Oxazole compounds as prostaglandin e2 agonists or antagonists
|
|
GB9826540D0
(en)
|
1998-12-02 |
1999-01-27 |
Darwin Discovery Ltd |
Process
|
|
AU2492500A
(en)
|
1999-01-06 |
2000-07-24 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Aspartic protease inhibitors, compositions, and associated therapeutic methods
|
|
JP2000302757A
(ja)
|
1999-04-16 |
2000-10-31 |
Shiseido Co Ltd |
Ｎ−置換ピペリジン誘導体
|
|
KR20020082896A
(ko)
|
2000-03-21 |
2002-10-31 |
스미스클라인 비참 코포레이션 |
프로테아제 억제제
|
|
US6900329B2
(en)
|
2001-03-21 |
2005-05-31 |
Schering Corporation |
MCH antagonists and their use in the treatment of obesity
|
|
WO2003006423A1
(en)
|
2001-07-11 |
2003-01-23 |
Elan Pharmaceuticals, Inc. |
N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
|
|
GB0121700D0
(en)
*
|
2001-09-07 |
2001-10-31 |
Univ Leicester |
Detection of fluorescence
|
|
NZ533107A
(en)
|
2001-11-08 |
2007-04-27 |
Upjohn Co |
N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
|
|
AU2003231765B9
(en)
|
2002-04-26 |
2010-01-28 |
Gilead Sciences, Inc. |
Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
|
|
AU2003238046A1
(en)
|
2002-06-27 |
2004-01-19 |
Actelion Pharmaceuticals Ltd |
Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
|
|
US7557137B2
(en)
|
2002-08-05 |
2009-07-07 |
Bristol-Myers Squibb Company |
Gamma-lactams as beta-secretase inhibitors
|
|
EP1537072A1
(en)
|
2002-09-10 |
2005-06-08 |
Pharmacia & Upjohn Company LLC |
Substituted aminoethers for the treatment of alzheimer s disease
|
|
EP2338490A3
(en)
|
2003-11-03 |
2012-06-06 |
Probiodrug AG |
Combinations useful for the treatment of neuronal disorders
|
|
US20070093492A1
(en)
|
2004-03-09 |
2007-04-26 |
Weir-Torn Jiaang |
Pyrrolidine derivatives
|
|
US20060063930A1
(en)
|
2004-08-20 |
2006-03-23 |
Agoston Gregory E |
Compositions and methods comprising proteinase activated receptor antagonists
|
|
AU2005294123C1
(en)
|
2004-10-07 |
2010-01-21 |
Vitae Pharmaceuticals, Inc. |
Diaminoalkane aspartic protease inhibitors
|
|
WO2006123725A1
(ja)
|
2005-05-19 |
2006-11-23 |
Astellas Pharma Inc. |
ピロリジン誘導体またはその塩
|
|
CN101356156B
(zh)
*
|
2005-11-14 |
2012-12-05 |
生命医药公司 |
天冬氨酸蛋白酶抑制剂
|
|
TWI411607B
(zh)
|
2005-11-14 |
2013-10-11 |
Vitae Pharmaceuticals Inc |
天門冬胺酸蛋白酶抑制劑
|
|
WO2007117560A2
(en)
|
2006-04-05 |
2007-10-18 |
Vitae Pharmaceuticals, Inc. |
Piperidine and morpholine renin inhibitors
|
|
WO2007117557A2
(en)
|
2006-04-05 |
2007-10-18 |
Vitae Pharmaceuticals, Inc. |
Diaminopropanol renin inhibitors
|
|
CL2007002689A1
(es)
|
2006-09-18 |
2008-04-18 |
Vitae Pharmaceuticals Inc |
Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
|
|
JP2010503682A
(ja)
|
2006-09-18 |
2010-02-04 |
ビテ ファーマシューティカルズ， インコーポレイテッド |
レニン阻害剤としてのピペリジン誘導体
|
|
WO2008156817A2
(en)
|
2007-06-20 |
2008-12-24 |
Vitae Pharmaceuticals, Inc. |
Renin inhibitors
|
|
EP2167609A1
(en)
|
2007-06-20 |
2010-03-31 |
Vitae Pharmaceuticals, Inc. |
Renin inhibitors
|
|
US7773441B2
(en)
*
|
2008-06-18 |
2010-08-10 |
Micron Technology, Inc. |
Memory malfunction prediction system and method
|
|
JP2011525488A
(ja)
|
2008-06-20 |
2011-09-22 |
ヴァイティー ファーマシューティカルズ，インコーポレイテッド |
レニン阻害剤およびその使用方法
|
|
CN102088850A
(zh)
*
|
2008-06-26 |
2011-06-08 |
生命医药公司 |
甲基2-((r)-(3-氯苯基)((r)-1-((s)-2-(甲氨基)-3((r)-四氢-2h-吡喃-3-基)丙基氨甲酰基)哌啶-3-基)甲氧基)氨基甲酸乙酯的盐
|